Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma

Journal of Clinical Oncology

Volumn 21, Issue 19, 2003, Pages 3559-3565

  Vos, Maaike J ^a   Hoekstra, Otto S ^a   Barkhof, Frederik ^a   Berkhof, Johannes ^a   Heimans, Jan J ^a   Van Groeningen, Cees J ^a   Vandertop, W Peter ^a   Slotman, Ben J ^a   Postma, Tjeerd J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

THALLIUM 201; DIAGNOSTIC AGENT; THALLIUM;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; GLIOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; ADULT; AGED; BRAIN TUMOR; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0141939071     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.001     Document Type: Article

References (29)

1. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
2. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
3. Perry JR, DeAngelis LM, Schold SC Jr, et al: Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 49:912-917, 1997
4. Zeltzer PM, Friedman HS, Norris DG, et al: Criteria and definitions for response and relapse in children with brain tumors. Cancer 56:1824-1826, 1985
5. Brada M, Yung WK: Clinical trial end points in malignant glioma: Need for effective trial design strategy. Semin Oncol 27:11-19, 2000
6. Vos MJ, Uitdehaag BMJ, Barkhof F, et al: Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826-830, 2003
7. Byrne TN: Imaging of gliomas. Semin Oncol 21:162-171, 1994
8. Kaplan RS: Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 10:175-178, 1998
9. Cairncross JG, Pexman JHW, Rathbone MP, et al: Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17:570-572, 1985
10. Forsyth PAJ, Petrov E, Mahallati H, et al: Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 15:2076-2081, 1997
11. Kumar AJ, Leeds NE, Fuller GN, et al: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377-384, 2000
12. Carvalho PA, Schwartz RB, Alexander E III, et al: Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 77:565-570, 1992
13. 99mTc-HMPAO. AJNR Am J Neuroradiol 12:1187-1192, 1991
14. Slizofski WJ, Krishna L, Katsetos CD, et al: Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. Cancer 74:3190-3197, 1994
15. Kosuda S, Fujii H, Aoki S, et al: Reassessment of quantitative thallium-201 brain SPECT for miscellaneous brain tumors. Ann Nucl Med 7:257-263, 1993
16. Mountz JM, Raymund PA, McKeever PE, et al: Specific localization of thallium 201 in human high-grade astrocytoma by microautoradiography. Cancer Res 49:4053-4056, 1989
17. Lorberboym M, Mandell LR, Mosesson RE, et al: The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 38:223-226, 1997
18. Roesdi MF, Postma TJ, Hoekstra OS, et al: Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 40:251-255, 1998
19. 201Tl SPET imaging in the follow-up of treatment for brain tumour: A sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 21:259-267, 2000
20. 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas. J Neurooncol 46:173-185, 2000
21. 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 59:81-90, 2002
22. DeAngelis LM: Brain tumors. N Engl J Med 344:114-123, 2001
23. Kappelle AC, Postma TJ, Taphoorn MJB, et al: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118-120, 2001
24. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001
25. Scott JN, Rewcastle NB, Brasher PM, et al: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183-188, 1999
26. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
27. van den Bent MJ, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy: Dutch Neuro-Oncology Group. Neurology 51:1140-1145, 1998
28. Simon JM, Cornu P, Boisserie G, et al: Brachytherapy of glioblastoma recurring in previously irradiated territory: Predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67-74, 2002
29. Grant R, Walker M, Hadley D, et al: Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: Size matters but speed does not. J Neurooncol 57:241-245, 2002